构建lncRNA模型探索膀胱癌的免疫治疗进展

赵 琪¹, 郭 峰¹, 熊 鹰²
1、长江大学医学部
2、荆州市第一人民医院科教科

摘要

由免疫相关的长非编码核糖核酸（irlncRNAs）组成的信号标记对预测膀胱癌患者预后具有一定的价值。本研究，检索了癌症基因组图谱(TCGA)的原始转录组数据，通过差异分析和共表达分析鉴定了具有差异表达的irlncRNA，并通过多变量分析鉴定了配对irlncRNA。然后比较曲线下面积，计算受试者工作特征曲线的AIC值，确定分界点，建立膀胱癌高、低危人群的最优判别模型。共鉴定出36对irlncRNA，其中10对纳入Cox回归模型。按分界点重新分组后，根据患者的不良生存结局、侵袭性临床病理特征、特定的肿瘤免疫浸润状态、化疗敏感性低和免疫抑制标志物的表达，可以更有效地区分它们。通过配对irlncRNA所建立的特征模型显示出良好的临床预测价值。

关键词

长链非编码 R N A ；生物标志物；膀胱癌；免疫微环境

参考

[1]Banerjee,S.and J.Southgate,Bladder organoids:a step towards personalisedcancer therapy?Transl Androl Urol,2019.8(Suppl 3):p.S300-s302.

[2]Tse,J.,et al.,Current advances in BCG-unresponsive non-muscle invasive bladder cancer.Expert Opin Investig Drugs,2019.28(9):p.757-770.

[3]Song,D.,et al.,Bladder cancer,a unique model to understand cancer immu-nity and develop immunotherapy approaches.JPathol,2019.249(2):p.151-165.

[4]Zhou,T.C.,et al.,A review of the PD-1/PD-L1 checkpoint in bladdercancer:From mediator of immune escape to target for treatment.Urol Oncol,2017.35(1):p.14-20.

[5]Singh,P.and P.Black,Emerging role of checkpoint inhibition in localized bladder cancer.Urol Oncol,2016.34(12):p.548-555.

[6]Crispen,P.L.and S.Kusmartsev,Mechanisms of immune evasion in bladder cancer.Cancer Immunol Immunother,2020.69(1):p.3-14.

[7]Choudhari,R.,et al.,Long noncoding RNAs in cancer:From discovery to therapeutic targets.Adv Clin Chem,2020.95:p.105-147.

[8]Sun,W.,N.M.Shen,and S.L.Fu,Involvement of lncRNA-mediated signalingpathway in the development of cervical cancer.Eur Rev Med Pharmacol Sci,2019.23(9):p.3672-3687.

[9]Chakraborty,S.,et al.,Harnessing the tissue and plasma lncRNA-peptidome to discover peptide-based cancer biomarkers.SciRep,2019.9(1):p.12322.

[10]Atianand,M.K.,D.R.Caffrey,and K.A.Fitzgerald,Immunobiology of Long Noncoding RNAs.Annu Rev Immunol,2017.35:p.177-198.

[11]Lopes,N.,et al.,Cracking the Breast Cancer Glyco-Code through Gly-can-Lectin Interactions:Targeting Immunosuppressive Macrophages.Int J Mol Sci,2021.22(4).

[12]Fridlender,Z.G.,et al.,Using macrophage activation to augment immu-notherapy of established tumours.Br J Cancer,2013.108(6):p.1288-97.

[13]Hong,W.,et al.,Immune-Related lncRNA to Construct Novel Signa-ture and Predict the Immune Landscape of Human Hepatocellular Carcinoma.Mol Ther Nucleic Acids,2020.22:p.937-947.

[14]Lima,L.,et al.,The role of functional polymorphisms in immune response genes as biomarkers of bacille Calmette-Guérin(BCG)immunotherapy outcome in bladder cancer:establishment of a predictive profile in a Southern Europe population.BJU Int,2015.116(5):p.753-63.

[15]Hoft,D.F.,et al.,PO and ID BCG vaccination in humans induce distinct mucosal and systemic immune responses and CD4(+)T cell transcriptomal molecu-lar signatures.Mucosal Immunol,2018.11(2):p.486-495.

[16]Kacew,A.and R.F.Sweis,FGFR3 Alterations in the Era of Immunotherapy for Urothelial Bladder Cancer.Front Immunol,2020.11:p.575258.

[17]Butt,S.U.and L.Malik,Role of immunotherapy in bladder cancer:past,present and future.Cancer Chemother Pharmacol,2018.81(4):p.629-645.

[18]han,A.,M.Soleimani,and S.S.Mandal,Long Noncoding RNA and Cancer:A New Paradigm.Cancer Res,2017.77(15):p.3965-3981.

[19]van Wersch,S.and X.Li,Stronger When Together:Clustering of Plant NLRDisease resistance Genes.Trends Plant Sci,2019.24(8):p.688-699.

[20]Lu,X.,et al.,Long non-coding RNA PICSAR knockdown inhibits the progression of cutaneous squamous cell carcinoma by regulating miR-125b/YAP1 axis.Life Sci,2021.274:p.118303.

[21]Huang,Y.,C.Zhang,and Y.Zhou,LncRNA MIR100HG promotes cancer cell proliferation,migration and invasion in laryngeal squamous cell carcinoma through the downregulation of miR-204-5p.Onco Targets Ther,2019.12:p.2967-2973.

[22]Zhou,M.,et al.,Computational recognition of lncRNA signature of tu-mor-infiltrating B lymphocytes with potential implications in prognosis and im-munotherapy of bladder cancer.Brief Bioinform,2020.

[23]Sveen,A.,et al.,ColoGuidePro:a prognostic 7-gene expression signature for stage III colorectal cancer patients.Clin Cancer Res,2012.18(21):p.6001-10.

[24]Jiménez-Sánchez,A.,et al.,Unraveling tumor-immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy.Nat Genet,2020.52(6):p.582-593.

[25]Kim,J.,M.P.Manspeaker,and S.N.Thomas,Augmenting the synergies of chemotherapy and immunotherapy through drug delivery.Acta Biomater,2019.88:p.1-14.

[26]Emens,L.A.and G.Middleton,The interplay of immunotherapy and chemotherapy:harnessing potential synergies.Cancer Immunol Res,2015.3(5):p.436-43.